Antileukotriene agents for the treatment of lung disease
about
Antagonists of the TMEM16A calcium-activated chloride channel modulate airway smooth muscle tone and intracellular calcium.Asthma phenotypes: the intriguing selective intervention with MontelukastCysteinyl Leukotrienes and Their Receptors: Emerging Therapeutic Targets in Central Nervous System DisordersUpdate on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell functionIn-vitro and in-vivo validation of ethnopharmacological uses of methanol extract of Isodon rugosus Wall. ex Benth. (Lamiaceae)Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients.Leukotriene receptor antagonists pranlukast and montelukast for treating asthma.Persisting eicosanoid pathways in rheumatic diseases.Cysteinyl Leukotrienes in Eosinophil Biology: Functional Roles and Therapeutic Perspectives in Eosinophilic DisordersMontelukast Induces Apoptosis-Inducing Factor-Mediated Cell Death of Lung Cancer Cells.Aerobic Exercise Reduces Asthma Phenotype by Modulation of the Leukotriene Pathway.Similar adverse events from two disparate agents implicate lipid inflammatory mediators for a role in anxiety states.A Review on the Medicinal Plant Dalbergia odorifera Species: Phytochemistry and Biological Activity.A Slippery Cause of a Slimy Problem: Mucin Induction by an Esterified Lipid.In vitro and in vivo evidence for an inflammatory role of the calcium channel TRPV4 in lung epithelium: Potential involvement in cystic fibrosis.Extracellular Vesicles as Conveyors of Membrane-Derived Bioactive Lipids in Immune System.Comparison of Effect of Leukotriene Biosynthesis Blockers and Inhibitors of Phosphodiesterase Enzyme in Patients with Bronchial Hyperreactivity.
P2860
Q27318373-A830852F-094E-40F0-8325-DA69E807E970Q28071735-BA1DFF66-FEBA-4805-A033-F80FE5CF15A6Q28278005-2E272DC5-C081-49E0-878A-E391A1E626C9Q28308192-49E7045E-C9AE-4EB7-8002-CB41CF3604FFQ33757657-E943D0D5-FDAE-4A7A-AF0E-AEF8BC799E28Q35100033-A13B277A-F277-4580-B7DF-F5EA3BB2D0EAQ36774324-6A6B7196-B8F8-46E2-9CE5-563AB53EF39AQ38172278-387F0112-6E68-4EDE-ADAE-064E74B9B080Q38186997-C7917EED-86AB-44D2-95B8-34C69944F3F2Q41044958-63CA7A5A-ECB2-444B-9B51-6AFA595139E2Q41181320-B471C3ED-21B6-41A8-8487-AF1F8F685822Q42726408-53139024-EC3C-4103-9635-CBE25C384B83Q46930021-30D9DC0B-0478-494D-942C-23F420EEE976Q48214506-FA2E690F-D4C6-4152-918E-0507012AB1BDQ49383994-E68A62D4-0AEC-43B0-94FA-95CE11121950Q51590583-A7D6CFA2-2B40-48DD-A5E9-DC4BCEF2DAA3Q52316727-872A0A4A-2E60-496D-AD14-2434C3B590C4Q55016315-88FEAC8E-CBCE-45C9-A0E8-C95551A25E56
P2860
Antileukotriene agents for the treatment of lung disease
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Antileukotriene agents for the treatment of lung disease
@ast
Antileukotriene agents for the treatment of lung disease
@en
Antileukotriene agents for the treatment of lung disease
@nl
type
label
Antileukotriene agents for the treatment of lung disease
@ast
Antileukotriene agents for the treatment of lung disease
@en
Antileukotriene agents for the treatment of lung disease
@nl
prefLabel
Antileukotriene agents for the treatment of lung disease
@ast
Antileukotriene agents for the treatment of lung disease
@en
Antileukotriene agents for the treatment of lung disease
@nl
P2860
P3181
P1476
Antileukotriene agents for the treatment of lung disease
@en
P2093
Jacob P Scott
P2860
P304
P3181
P356
10.1164/RCCM.201301-0023PP
P407
P577
2013-09-01T00:00:00Z